Interview: MedPacto Sees Robust Prospects For ‘Best-In-Class’ ALK5 Inhibitor
MedPacto is preparing for a critical Phase II US study with its potentially best-in-class ALK5 inhibitor, a potential rival to a Lilly molecule and that will be central to the South Korean bioventure’s long-term ambitions to become a global player.
You may also be interested in...
After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.